Kevin Tang Acquires 343,620 Shares of Aurinia Pharmaceuticals (NASDAQ:AUPH) Stock

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) (TSE:AUP) CEO Kevin Tang purchased 343,620 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The shares were bought at an average price of $15.28 per share, with a total value of $5,250,513.60. Following the completion of the acquisition, the chief executive officer owned 12,838,101 shares of the company’s stock, valued at $196,166,183.28. This trade represents a 2.75% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Kevin Tang also recently made the following trade(s):

• On Tuesday, June 2nd, Kevin Tang acquired 206,005 shares of Aurinia Pharmaceuticals stock. The stock was bought at an average price of $15.28 per share, for a total transaction of $3,147,756.40.
• On Friday, May 29th, Kevin Tang bought 264,981 shares of Aurinia Pharmaceuticals stock. The stock was bought at an average price of $15.31 per share, with a total value of $4,056,859.11.

Aurinia Pharmaceuticals Stock Up 0.5%

AUPH stock traded up $0.08 during midday trading on Tuesday, reaching $15.39. The company had a trading volume of 1,304,499 shares, compared to its average volume of 1,232,305. The company has a 50 day moving average of $15.51 and a two-hundred day moving average of $15.25. The company has a market capitalization of $1.98 billion, a P/E ratio of 7.09 and a beta of 1.41. Aurinia Pharmaceuticals Inc has a 1 year low of $7.28 and a 1 year high of $16.88. The company has a current ratio of 5.55, a quick ratio of 5.01 and a debt-to-equity ratio of 0.08.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings results on Thursday, May 7th. The biotechnology company reported $0.25 EPS for the quarter, beating the consensus estimate of $0.18 by $0.07. Aurinia Pharmaceuticals had a net margin of 99.97% and a return on equity of 26.62%. The business had revenue of $77.71 million for the quarter, compared to analysts’ expectations of $76.98 million. On average, equities research analysts expect that Aurinia Pharmaceuticals Inc will post 0.82 earnings per share for the current fiscal year.

Institutional Trading of Aurinia Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in AUPH. JPMorgan Chase & Co. lifted its stake in shares of Aurinia Pharmaceuticals by 21.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 533,290 shares of the biotechnology company’s stock valued at $5,893,000 after purchasing an additional 94,941 shares during the last quarter. Tudor Investment Corp ET AL acquired a new position in Aurinia Pharmaceuticals during the third quarter worth $729,000. Ritholtz Wealth Management raised its holdings in Aurinia Pharmaceuticals by 206.2% during the fourth quarter. Ritholtz Wealth Management now owns 258,816 shares of the biotechnology company’s stock valued at $4,128,000 after buying an additional 174,301 shares in the last quarter. Navellier & Associates Inc. bought a new position in Aurinia Pharmaceuticals during the third quarter valued at about $926,000. Finally, SG Americas Securities LLC increased its holdings in shares of Aurinia Pharmaceuticals by 69.6% during the 4th quarter. SG Americas Securities LLC now owns 136,224 shares of the biotechnology company’s stock valued at $2,173,000 after acquiring an additional 55,903 shares during the last quarter. 36.83% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Separately, Weiss Ratings lowered Aurinia Pharmaceuticals from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Friday, May 15th. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. According to MarketBeat.com, Aurinia Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $17.25.

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc is a clinical?stage biopharmaceutical company focused on developing and commercializing therapies for autoimmune diseases. The company’s proprietary molecule, voclosporin, is designed to selectively inhibit calcineurin and reduce inflammation associated with autoimmune responses. Aurinia operates research and development facilities in Canada and the United States, leveraging collaborations with academic institutions and contract research organizations to advance its clinical pipeline.

The company’s lead product, voclosporin (marketed as LUPKYNIS), received approval from the U.S.